

Nov 19, 2020

## © PBMC- 05 - In Vitro Culture of TEFF+TREG - Cytokine **Production by TEFF**

Marco Cosentino<sup>1</sup>, Elisa Storelli<sup>1</sup>, Alessandra Luini<sup>1</sup>, Massimiliano LM Legnaro<sup>1</sup>, Emanuela Rasini<sup>1</sup>, Marco Ferrari<sup>1</sup>, Franca Marino<sup>1</sup>

<sup>1</sup>Center for Research in Medical Pharmacology, University of Insubria (Varese, Italy)



dx.doi.org/10.17504/protocols.io.bmhxk37n



Farmacologia Medica

ABSTRACT

List of published work using this procedure:

■ Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., Sturchio, A., Mauri, M., Bono, G., Marino, F., & Cosentino, M. (2018). Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. Journal of neuroinflammation, 15(1), 205. https://doi.org/10.1186/s12974-018-1248-8

dx.doi.org/10.17504/protocols.io.bmhxk37n

PROTOCOL CITATION

Marco Cosentino, Elisa Storelli, Alessandra Luini, Massimiliano LM Legnaro, Emanuela Rasini, Marco Ferrari, Franca Marino 2020. PBMC- 05 - In Vitro Culture of TEFF+TREG - Cytokine Production by TEFF.

protocols.io

https://dx.doi.org/10.17504/protocols.io.bmhxk37n

LICENSE

 $_{
m ullet}$  This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Sep 18, 2020

LAST MODIFIED

Nov 19, 2020

PROTOCOL INTEGER ID

42263

**ABSTRACT** 

Laminar Flow Hood

Humidified 37°C, 5% CO2 incubator

List of published work using this procedure:

- Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., Sturchio, A., Mauri, M., Bono, G., Marino, F., & Cosentino, M. (2018). Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. Journal of neuroinflammation, 15(1), 205. https://doi.org/10.1186/s12974-018-1248-8
- 1 Isolate TEFF and TREG with Miltenyi Kit according to the protocol PBMC- 03.
- 2 Count both TEFF and TREG following the appropriate protocol.
- 3 Use sterile 96-well round bottom plates.

[Consider that these plates can contain a volume of maximum 250 $\mu$ L]

4 Centrifuge TEFF and TREG at <a>3</a>1200 x g, Room temperature , 00:05:00

Allegra AVANTI 30
Centrifuge
Beckman Coulter Beckman Italy

- 5 Resuspend TEFF and TREG in complete culture medium at a concentration of  $1x10^6/mL$ .
- According to the experimental design, activate a desired number of wells containing TEFF cells with PHA 5μg/ml (final concentration) and IL-2 40 ng/mL (final concentration) by diluting the stock aliquots. Leave also wells of TEFF unstimulated (resting control).
- Put **TEFF-CPD labeled cells** and **TREG cells** in the 96-well plate at a **ratio of 1:1** (for example, 0.1x10<sup>6</sup> TEFF + 0.1x10<sup>6</sup> TREG) and activate the cells if the well directly (see step 7 for concentrations): include **1 control co-culture** (not treated with test substance) and **treated co-cultures** (+test substance) according to your experimental design.
- 8 Include also a culture of **resting** and **activated TEFF alone** (for example 0.2x10<sup>6</sup>per well), as control for the subsequent ELISA test.
- 9 Put the plate in a § 37 °C incubator for 48 hours.
- At the end of cell culture, **collect the supernatant** in eppendorf tubes (1.5mL) and **centrifuge them** at **1200 x g, Room temperature**, **00:05:00** in order to eliminate any residual cells.

Allegra AVANTI 30 Centrifuge

Beckman Coulter Beckman Italy

 $11 \qquad \hbox{Collect $\textbf{supernatants}$ and $\textbf{store them at -80°C}$ until ELISA assay is performed.}$